New blood vessels that grow in response to cardiac ischemia appeared in a mouse model to be partly from clonal expansion of endothelial cells — a discovery that might open up new treatment pathways, researchers wrote in Circulation Research.
“Hot yoga” isn’t better for the heart than yoga done at regular room temperature, researchers found. (Cardiovascular Business)
Nearly half of out-of-hospital cardiac arrest survivors struggle to return to work and deal with emotions and cognitive impairment afterward, a trial substudy showed. (Cardiovascular Business)
Acer Therapeutics will pursue FDA approval of beta blocker celiprolol (Edsivo) based on 7-year-old data after gaining granted orphan drug status for the rare vascular condition Ehlers-Danlos Syndrome, BioPharmaDIVE reports.
After failing to improve key endpoints in the phase III LIBERTY trial, ubenimex will be abandoned for development as a pulmonary arterial hypertension treatment. (Reuters)
The SynchroMed II implantable pump for infusion of baclofen was better for post-stroke spasticity pain than taking the medication orally, the SISTERS trial showed. (Minneapolis Star Tribune)
The mean arterial pressure target during on-pump cardiopulmonary bypass didn’t affect volume or number of new cerebral infarcts, a small randomized trial showed. (Circulation)
A disposable centrifugal heart pump, FloPump 32, was cleared by the FDA for use with the RotaFlow console on a stand-alone basis or as part of a heart-lung machine setup. (MedGadget)
European regulators cleared the Advisor HD Grid sensor-enabled mapping catheter for cardiac ablation. (MedGadget)
The FDA issued a safety alert that the Zoll LifeVest 4000 wearable cardioverter-defibrillator can fail if immediate action to replace the device isn’t taken after a bland “call for service” error message.
A second lot of amiodarone (Nexterone) is being recalled because of the presence of particulates, the FDA noted.
Researchers developed a biodegradable pressure sensor that could be used for chronic heart failure and other conditions without need for a second surgical procedure to remove it, although the current 4-week durability seen in mice is still being worked on. (MedGadget)
A cardiovascular conduit that expands as children grow, a nitric oxide generator to treat severe pediatric pulmonary hypertension, and a device to quantify leaflet coaptation height in kids’ heart valve repairs were all awarded grants and development aid from industry, the Boston Pediatric Device Consortium announced.